Minerva Rockets On Positive PhIIb Data – Is A Big Pharma Partnership On The Horizon?
Executive Summary
Minerva Neurosciences Inc.'s schizophrenia drug that targets patients with negative symptoms, an indication with high unmet need and no approved treatments, has met primary and secondary endpoints in a Phase IIb trial – positioning the company well for access to an open market and marking it as an attractive M&A target.